Xi'an Kangtuo Medical multiple shareholders intend to reduce holdings, totaling no more than 2.62% of shares; the controlling shareholder and employee shareholding platform each reduce holdings by 1%.

Log in to the Sina Finance app, search for 【disclosure of information】 to view evaluation tiers

On March 31, 2026, Xi’an Kangtuo Medical Technology Co., Ltd. (hereinafter referred to as “Kangtuo Medical”) released an announcement on its shareholders’ planned reduction of holdings. The company’s controlling shareholder and actual controller, Hu Liren; the employee shareholding platform Xi’an Aying Enterprise Management Consulting Partnership (Limited Partnership) (hereinafter referred to “Xi’an Aying”); director and general manager Zhu Hailong; director and deputy general manager Zhao Ruoyu; and multiple other shareholders plan to reduce their holdings of shares through centralized bidding or block trades within the next 3 months, with a total reduction of no more than 2.1224 million shares, representing 2.62% of the company’s total share capital.

Details of the reduction plan

This reduction plan involves four shareholders. The specific arrangements are as follows:

• | | Zhu Hailong | No more than 300,000 | No more than 0.37% | Centralized bidding, block trades | 2026/4/23～2026/7/22 | Obtained prior to the IPO | Personal funding needs | | Zhao Ruoyu | No more than 200,000 | No more than 0.25% | Centralized bidding, block trades | 2026/4/23～2026/7/22 | Obtained prior to the IPO | Personal funding needs |

The announcement shows that this reduction will be implemented within 3 months after 15 trading days from the date of the plan announcement. If the company’s stock is suspended during this period, the actual reduction timeframe will be extended accordingly.

Basic information on shareholders’ holdings

As of the date the announcement was disclosed, the shareholders’ holdings are as follows:

Among them, Hu Liren, as the company’s controlling shareholder, actual controller, and chairman of the board, also serves as the executor in the Xi’an Aying partnership. Zhu Hailong and Zhao Ruoyu are both directors and senior management personnel of the company. All shares held by the above shareholders have already been listed and are freely tradable.

Risk warning

In its announcement, Kangtuo Medical stated that the planned reduction is determined independently by the shareholders based on their own capital needs. During the reduction period, the shareholders will decide whether to implement it and the specific implementation method based on factors such as market conditions and the company’s share price. Therefore, there is uncertainty regarding the reduction quantity and the price.

The announcement also emphasized that this reduction will not lead to any change in the company’s controlling shareholder or actual controller, and will not have a material impact on the company’s ongoing and stable operations. The company currently has no major negative matters or material risks. Shareholders will strictly comply with relevant regulations such as the Securities Law and the Shanghai Stock Exchange’s rules for listing shares on the STAR Market, and will promptly fulfill their information disclosure obligations.

Statement: The market involves risk; invest cautiously. This article is automatically published by an AI large model based on third-party databases and does not represent the views of Sina Finance. Any information appearing in this article is for reference only and does not constitute personal investment advice. If there is any discrepancy, please refer to the actual announcement. If you have any questions, please contact biz@staff.sina.com.cn.

Click to view the full text of the original announcement>>

A wealth of information and precise analysis—right on the Sina Finance app

Responsible editor: Xiao Lang Express News